NASDAQ · ETON

Eton Pharmaceutcials, Inc.

$42.31 -$0.28 (-0.66%) 1D Pre-market

Key Metrics

$1.17B
Market cap
P/E · TTM
$86.93M
Revenue · TTM
−$1.48M
Net income
EPS · TTM $-0.05
Dividend yield
Free cash flow $15.43M
Beta · 1Y 0.40
EBITDA · TTM −$1.44M
Gross margin 54.8%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 17
    The stock moved +13.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 17
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 1
    The stock moved +19.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 1

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.17B
Enterprise value$1.18B
Shares outstanding27.4M
52-wk range$13.78 – $44.91
Avg volume · 20D240.7K
Net cash −$11.09M
Book value / share$1.14
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Eton Pharmaceutcials, Inc.
IPO dateNov 14, 2018
Employees44

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S13.42
P/FCF75.60
EV/EBITDA
EV/Sales13.55
Graham №

Profitability

Gross 54.8%
Operating -1.7%
Net -1.7%
FCF 17.8%
ROE / ROIC -5.4% · -3.5%

Financial Health

Current ratio1.21
Quick ratio0.88
Debt / equity1.00
Debt / EBITDA -21.43
Net cash −$11.09M
Working capital$9.07M

Cash Flow · TTM

Operating CF $15.84M
Capex −$408.00K
Free cash flow $15.43M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

9.8
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings